<DOC>
	<DOCNO>NCT00265109</DOCNO>
	<brief_summary>The purpose study assess usefulness medication ( Levetiracetam ) people body dysmorphic disorder .</brief_summary>
	<brief_title>Effectiveness Levetiracetam Treatment Body Dysmorphic Disorder</brief_title>
	<detailed_description>Body dysmorphic disorder ( BDD ) , perceive defect appearance ( e.g. , `` large '' nose facial `` scar '' ) , relatively common disorder cause mark distress impairment functioning . Recent data suggest adult BDD may respond serotonin reuptake inhibitor ( SRIs ) ; however , response SRIs often partial . About one third patient respond SRI . Furthermore , patient may stop take SRIs side effect ( e.g. , sexual side effect ) . For reason , additional monotherapy SRI augmentation strategy greatly need . Levetiracetam primarily use antiseizure medication wider safety margin antiepileptic . Preliminary scientific study may suggest may helpful certain psychiatric symptom disorder . In present study propose obtain pilot data 1 ) levetiracetam monotherapy 2 ) levetiracetam augmentation SRIs patient BDD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Body Dysmorphic Disorders</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Men woman age 1865 ; Current DSMIV BDD delusional variant ( delusional disorder , somatic type ) least 3 month ; A minimum total score 20 YaleBrown Obsessive Compulsive Scale Modified BDD ( BDDYBOCS ) ( 19 ) ; Suitable treatment outpatient set Unstable medical illness , include renal failure dialysis ; Myocardial infarction within 6 month ; Current pregnancy lactation , inadequate contraception woman childbearing potential ; A need prn benzodiazepine , another antiepileptic medication , anticipated change dose concomitant medication receive treatment levetiracetam ; Clinically significant suicidality , include suicide attempt within past two month ; Lifetime history DSMIV dementia , schizophrenia , DSMIV psychotic disorder attributable BDD ; Current recent ( past 3 month ) DSMIV substance abuse dependence ; Initiation ongoing psychotherapy mental health professional within 3 month prior study baseline ; Ongoing cognitivebehavioral therapy mental health professional ; Previous treatment levetiracetam ; Treatment investigational medication , depot neuroleptic , ECT within past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>body dysmorphic disorder</keyword>
	<keyword>levetiracetam</keyword>
</DOC>